Sally C. M. Lau

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Ferdinandos Skoulidis, Haniel A. Araújo, Minh Truong et al. · Nature · 2024 · 117 citations · Full text

Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy

Giannis Mountzios, Longhua Sun, Byoung Chul Cho et al. · New England Journal of Medicine · 2025 · 83 citations · Full text

KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition

Yuanwang Pan, Han Han, Hai Hu et al. · Cancer Cell · 2022 · 81 citations · Full text

Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non–small cell lung cancer: A real-world multicentre study

Antoine Desîlets, Félix Blanc‐Durand, Sally C. M. Lau et al. · European Journal of Cancer · 2020 · 76 citations

Real-world Multicentre Study, Medicine, Historical Cohort +9

Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors

Sally C. M. Lau, Aline Fusco Fares, Lisa W. Le et al. · Clinical Lung Cancer · 2021 · 63 citations

Medicine, Immune Checkpoint Inhibitors, Immunology +6